Available Studies

Join the Baltimore Early Phase Unit in an upcoming study to evaluate the safety and tolerability of a new inhaler formulation compared to Pulmicort Flexhaler dry-powder inhaler (DPI) for the potential treatment of asthma.

You must weigh between 110 lbs - 220 lbs

This study involves

1 screening visit; spirometry at screening

2 in-house stays of 3 days/ 2 nights and

1 outpatient visit

*Screening could last 4 hours or more*

Screening dates: 20, 22, 23 and 28 May

Cohort 1 (In-house stay): 5-7 Jun, 10-12 Jun

Cohort 2 (In-house stay): 12-14 Jun, 17-19 Jun

*Must be available for both cohorts*

We are seeking healthy normal volunteers between the ages of 18 and 55 to participate in a clinical trial for the treatment against diphtheria toxin. The study involves 1 screening visit, 1 in-house stay of 5 days/4 nights and 5 outpatient visits. If you qualify, you can earn up to $3,300 for completing the study.

Screenings on May 13th, 14th, 15th, 16th, 17th, 20th, 21st, 22nd, 23rd,

Admission dates: May 27th, May 29th, May 30th.

This study involves 2 screening visits, 1 in-house stay of 9 nights / 8 days and 1 outpatient follow-up. The 2nd screening visit will be scheduled upon receipt of genotype lab results (within 10-20 days of 1st visit). no study participation for 90 days prior to screening You must be of African Descent.

Cohort 19: Screen May 20, 22 in-house stay 3 -11 Jun follow up 17 Jun

Cohort 20: Screen May 27,28 in-house stay 10 - 18 Jun follow up 24 Jun

This study is for patients with definite idiopathic PD taking oral PD medication. The purpose of this study is to learn about the safety, tolerability, and pharmacokinetics (the amount of drug exposure in your body determined through blood tests) of ABBV-951 at four dose levels in patients with Parkinson’s Disease given as 72 hour subcutaneous (under your skin)infusions using infusion sets and syringe pumps. To take part, you will be required to complete 1 screening visit. If you qualify after the screening visit, site staff will contact you regarding when you will be able to start the study.

Study dates flexible

The purpose of this study is to assess the safety and tolerability of an investigational drug in subjects with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). The study drug is a type of antibody that is directed against a specific receptor within the immune system that has been found to be involved in systemic autoimmune diseases such as SLE and RA.

Volunteers in the study will receive a single dose of the study drug via an IV (intravenous) infusion. To determine if you qualify for the study you must first complete a screening visit.

Participation in this study involves 1 screening visit, 1 inpatient admission to our clinic for 2 days/1 night for dosing, and a minimum of 8 outpatient visits spread out over 16 weeks.

Visit dates are flexible

Join a contact registry for upcoming Parkinson's Disease studies!

Study dates TBD

Join a contact registry for upcoming Rheumatoid Arthritis studies!

Study dates TBD

Join a contact registry for upcoming Lupus studies!

Study Dates TBD

This study involves 1 screening visit one in-house stay of 10 days / 9 nights and 1 follow up visit

The study is to assess the bioavailability of Gilteritinib following a single dose of ASP2215 Oral Suspension and ASP 2215 mini-tablets compared to a single dose of 40mg Gilteritinib

Females must be either Postmenopausal for at least 12 months or have documented hysterectomy,bilateral salpingectomy or bilateral opphorectomy